Literature DB >> 25757956

Total 25(OH) vitamin D, free 25(OH) vitamin D and markers of bone turnover in cirrhotics with and without synthetic dysfunction.

Jennifer C Lai1, Daniel D Bikle1,2, Blanca Lizaola3, Hilary Hayssen1, Norah A Terrault1, Janice B Schwartz1,4.   

Abstract

BACKGROUND & AIMS: Current clinical assays for total 25-hydroxy (OH) vitamin D measure vitamin D bound to vitamin D-binding protein (DBP) and albumin plus unbound ('free') D. We investigated the relationship between total and free 25(OH)D with bone metabolism markers in normal (>3.5 g/dl) vs. low (≤3.5 g/dl) albumin cirrhotics.
METHODS: Eighty-two cirrhotics underwent measurement of free and total 25(OH)D by immunoassay, DBP and markers of bone metabolism [intact parathyroid hormone (iPTH), C-telopeptide (CTX), bone-specific alkaline phosphatase (BSAP), osteocalcin, amino-terminal pro-peptide of type 1-collagen (P1NP)]. Pearson's coefficients assessed relevant associations.
RESULTS: Cirrhotics with low (n = 54) vs. normal (n = 28) albumin had lower total 25(OH)D (12.1 vs. 21.7 ng/ml), free 25(OH)D (6.2vs.8.6 pg/ml) and DBP(91.4 vs. 140.3 μg/ml) [P < 0.01 for each]. iPTH was similar in low and normal albumin groups (33 vs. 28 pg/ml; P = 0.38), although serum CTX(0.46vs.0.28 ng/ml) and BSAP(31.7 vs. 24.8 μg/L) were increased (P < 0.01). An inverse relationship was observed between total 25(OH)D and iPTH in normal (r = -0.47, P = 0.01) but not low albumin cirrhotics (r = 0.07, P = 0.62). Similar associations were seen between free 25(OH)D and iPTH(Normal: r = -0.46, P = 0.01; Low: r = -0.03, P = 0.84). BSAP, osteocalcin and P1NP were elevated above the normal range in all cirrhotics but not consistently associated with total or free 25(OH)D.
CONCLUSIONS: Cirrhotics with low vs. normal albumin have lower levels of DBP, total and free 25(OH)D. The expected relationship between total or free 25(OH)D with iPTH was observed in normal but not in low albumin cirrhotics, demonstrating that total 25(OH)D is not an accurate marker of bioactive vitamin D status in cirrhotics with synthetic dysfunction. Additional investigation into the role of vitamin D supplementation and its impact on bone mineral homoeostasis in this population is needed.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  albumin; free hormone hypothesis; metabolic bone disease; parathyroid hormone; vitamin D-binding protein

Mesh:

Substances:

Year:  2015        PMID: 25757956      PMCID: PMC4567539          DOI: 10.1111/liv.12819

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  25 in total

1.  Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Gastroenterol Hepatol       Date:  2007-01-10       Impact factor: 11.382

Review 2.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

3.  American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders.

Authors: 
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

4.  Free, and not total, 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes.

Authors:  D D Bikle; E Gee
Journal:  Endocrinology       Date:  1989-02       Impact factor: 4.736

Review 5.  Vitamin d deficiency in patients with chronic liver disease and cirrhosis.

Authors:  Lei Yuan Lim; Naga Chalasani
Journal:  Curr Gastroenterol Rep       Date:  2012-02

6.  Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology.

Authors:  Mikkel Malham; Søren Peter Jørgensen; Peter Ott; Jørgen Agnholt; Hendrik Vilstrup; Mette Borre; Jens F Dahlerup
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

7.  A comparison of measured and calculated free 25(OH) vitamin D levels in clinical populations.

Authors:  J B Schwartz; J Lai; B Lizaola; L Kane; S Markova; P Weyland; N A Terrault; N Stotland; D Bikle
Journal:  J Clin Endocrinol Metab       Date:  2014-01-31       Impact factor: 5.958

Review 8.  Bone disorders in chronic liver disease.

Authors:  Jane Collier
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

9.  Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment.

Authors:  D S Matloff; M M Kaplan; R M Neer; M J Goldberg; W Bitman; H J Wolfe
Journal:  Gastroenterology       Date:  1982-07       Impact factor: 22.682

10.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

View more
  19 in total

1.  Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations.

Authors:  Janice B Schwartz; J Christopher Gallagher; Rolf Jorde; Vivian Berg; Jennifer Walsh; Richard Eastell; Amy L Evans; Simon Bowles; Kim E Naylor; Kerry S Jones; Inez Schoenmakers; Michael Holick; Eric Orwoll; Carrie Nielson; Martin Kaufmann; Glenville Jones; Roger Bouillon; Jennifer Lai; Davide Verotta; Daniel Bikle
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

2.  Free versus total serum 25-hydroxyvitamin D in a murine model of colitis.

Authors:  D P Larner; C Jenkinson; R F Chun; C S J Westgate; J S Adams; M Hewison
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-30       Impact factor: 4.292

3.  Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy?

Authors:  G Mazziotti; F Maffezzoni; A Giustina
Journal:  Endocrine       Date:  2016-02-22       Impact factor: 3.633

Review 4.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

5.  Association of free vitamin D3 concentrations and asthma treatment failures in the VIDA Trial.

Authors:  John J Lima; Mario Castro; Tonya S King; Jason E Lang; Victor E Ortega; Stephen P Peters; Loren C Denlinger; Elliot Israel; Christine A Sorkness; Michael E Wechsler; Sally E Wenzel; Lewis J Smith
Journal:  Ann Allergy Asthma Immunol       Date:  2018-06-14       Impact factor: 6.347

6.  Comparison of Two ELISA Methods and Mass Spectrometry for Measurement of Vitamin D-Binding Protein: Implications for the Assessment of Bioavailable Vitamin D Concentrations Across Genotypes.

Authors:  Michelle R Denburg; Andrew N Hoofnagle; Samir Sayed; Jayanta Gupta; Ian H de Boer; Lawrence J Appel; Ramon Durazo-Arvizu; Krista Whitehead; Harold I Feldman; Mary B Leonard
Journal:  J Bone Miner Res       Date:  2016-06       Impact factor: 6.741

Review 7.  Vitamin D Assays.

Authors:  Daniel D Bikle
Journal:  Front Horm Res       Date:  2018-03-29       Impact factor: 2.606

Review 8.  VITAMIN D BINDING PROTEIN AND 25-HYDROXYVITAMIN D LEVELS: EMERGING CLINICAL APPLICATIONS.

Authors:  Navinder K Jassil; Anupa Sharma; Daniel Bikle; Xiangbing Wang
Journal:  Endocr Pract       Date:  2017-01-17       Impact factor: 3.443

Review 9.  Vitamin D metabolites in captivity? Should we measure free or total 25(OH)D to assess vitamin D status?

Authors:  Daniel Bikle; Roger Bouillon; Ravi Thadhani; Inez Schoenmakers
Journal:  J Steroid Biochem Mol Biol       Date:  2017-01-16       Impact factor: 4.292

10.  Effects of Vitamin D Supplementation on Serum 25-Hydroxyvitamin D Concentrations in Cirrhotic Patients: A Randomized Controlled Trial.

Authors:  Stefan Pilz; Csilla Putz-Bankuti; Martin Gaksch; Walter Spindelboeck; Marius Haselberger; Florian Rainer; Andreas Posch; Philipp Kreuzer; Tatjana Stojakovic; Vanessa Stadlbauer; Barbara Obermayer-Pietsch; Rudolf E Stauber
Journal:  Nutrients       Date:  2016-05-10       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.